We use cookies to ensure that we give you the best experience on our website.
When you use our platform without an account you need to read and accept the
Terms of Service, Data Policy and Disclaimer(s).
Medical - Diagnostics & Research
Healthcare
BE
Herstal
IR
ISIN
Market Cap.:85.6 M
XS
Market Capitalization - Sizes
Here you can see how we classify a market capitalization.
XS
< 100 Mil.
S
> 100 Mil.
M
> 1 Bil.
L
> 10 Bil.
XL
> 100 Bil.
P/E:-1.58
x-0.95Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Concrete for "Diagnostics & Research" in Belgium
EPS: -1.4150,
P/E: -0.9500
EPS:-1.91
x
0.74
Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Concrete for Diagnostics & Research in Belgium
EPS: -1.4150,
P/E: -0.9500
Earnings Call
No. The last one was
10 months, 1 week ago
Dividend Waiting Time
We compute the average time difference between dividend payments
and assign an indicator that holds a general grade for that frequency.
Low
Average time between dividend payments is less than 3 months.
Neutral
Average time between dividend payments is between 3 to 6 months.
High
Average time between dividend payments is more than 6 months.
n.A.
Latest Dividends History
Each bar represents a dividend payment made within the last 12 months, with the bar's height relative to the maximum dividend paid within that timeframe.
See all Dividends.
Yield
Payout
Volume LevelVolume Deviation Rating System (VDRS)
We compare the 15-minute delayed volume to the average volume and grade the percentual deviation.
High
Deviation >= 20%
Moderate High
Deviation between 10% to 20%
Moderate
Deviation between -10% to 10%
Moderate Low
Deviation between -20% to -10%
Low
Deviation between <= -20%
μ 40,428
14,079
Moderate Low
Performance Ranks (Intraday)A system to benchmark MDXH.BR's relative intraday performance.
Each star represents "20% have worse results", e.g. 4/5 stars symbolize that the corporate had a better result than 80% of the benchmark compotion.
Belgium:
144th
out of
146
Healthcare:
759th
out of
792
Diagnostics & Research:
48th
out of
49
Peer Group:
3rd
out of
3
About
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, …
About
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, …